Dyslipidemia News and Research

RSS

Dyslipidemia is a disruption in the amount of lipids in the blood.

Pfizer and Bristol-Myers Squibb finalize agreement on metabolic disorders program

Pfizer Inc. and Bristol-Myers Squibb Company have announced that they have finalized a definitive agreement for the worldwide collaboration to research, develop and commercialize DGAT-1 inhibitors, a collaboration first announced on April 26, 2007.

28 Aug 2007

Genomic factors may play a role in alcohol and tobacco use

Alcohol and smoking can be harmful, if not deadly. While the desire for these substances can be due to environmental cues, genomic factors also play an important role.

13 Aug 2007

Quality of treatment guidelines

Practising physicians are nowadays presented with official guidelines on the treatments they should give their patients.

7 Aug 2007

Hydroxychloroquine may reduce risk of diabetes in patients with rheumatoid arthritis

Preliminary research suggests that use of the anti-malarial drug hydroxychloroquine may help reduce the risk of the development of diabetes in patients with rheumatoid arthritis, according to a study in the July 11 issue of JAMA .

11 Jul 2007

Rosuvastatin well tolerated by a broad range of patients with dyslipidemia

The safety and tolerability of rosuvastatin were assessed using data from 16,876 patients who received rosuvastatin 5-40 mg in a multinational phase II/III/IIIb/IV program, representing 25,670 patient-years of continuous exposure to rosuvastatin. An integrated database, consisting of 33 trials whose databases were locked up to and including September 16, 2005, was used to examine adverse events and laboratory data.

9 May 2007

Abbott submits NDA for combination Niaspan/Simvastatin tablet

Abbott has submitted a New Drug Application to the Food and Drug Administration for a fixed-dose combination (Simcor) of Niaspan (extended-release niacin) and simvastatin.

24 Apr 2007

Lexicon-Genentech reveals potential therapeutic targets

Lexicon Genetics Incorporated has announced that data was presented highlighting potential therapeutic targets related to its collaboration with Genentech, Inc. at the Society for Biomolecular Sciences 13th Annual Conference & Exhibition in Montreal, Canada.

19 Apr 2007

Most promising drugs in development for metabolic syndrome

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that emerging agents from Metabolex/Johnson & Johnson, Merck, Novartis, and Amylin/Eli Lilly are among the most promising drugs in development for metabolic syndrome.

11 Apr 2007

PPD licenses dyslipidemia statin from Ranbaxy

Ranbaxy Laboratories and PPD, Inc. have announced that PPD has acquired an exclusive worldwide license to develop, manufacture and market Ranbaxy's novel statin for the treatment of dyslipidemia.

27 Feb 2007

Twin study on the increased cardiometabolic risk in obesity

A unique monozygotic twin study by researchers from the Finnish Twin Cohort, Helsinki University Central Hospital, and VTT Technical Research Centre of Finland found that obesity, already in its early stages and independent of genetic influences, is associated with deleterious alterations in the lipid metabolism known to facilitate atherogenesis, inflammation and insulin resistance.

15 Feb 2007

More fat people than starving in the world

At an International Congress on Obesity, in Sydney, Australia, chairman Professor Paul Zimmet has said that obesity is no longer a problem limited to America and other developed countries but has reached the scale of a global epidemic.

4 Sep 2006

Prevalence of Peyronie's disease in men with erectile dysfunction

Peyronie's disease (PD) is a localized connective tissue disorder that primarily affects the tunica albuginea and the areolar space between the tunica albuginea and erectile tissue.

17 Apr 2006

Rimonabant produces sustained weight loss long term

Use of the weight-loss medication rimonabant produced modest yet sustained weight loss after 2 years, and improved HDL cholesterol and triglyceride levels, according to a study in the February 15 issue of JAMA: The Journal of the American Medical Association.

17 Feb 2006

Amputation among patients with diabetes mellitus - increased risk of neuropathy and diabetic ulcers in taller patients

Patients with diabetes mellitus are at risk of leg ulcers. These eventually become infected, respond poorly to treatment and often require amputation of the foot or part of the leg.

7 Feb 2006

Statins account for 81% of first-line therapies for dyslipidemia treatment

Decision Resources, Inc., finds that despite the dominant market position of statins in the treatment of dyslipidemia, only 81% of patients receive a statin as a first-line therapy for the disease.

23 Jan 2006

Scientists identify molecular link between body fat and blood lipids

Scientists from Wageningen University in the Netherlands have discovered that a factor released from body fat, which they call Fasting-Induced Adipose Factor or FIAF, has a major impact on blood levels of HDL and triglycerides in mice.

10 Nov 2005

Teen-age boys with type 1 diabetes showed evidence of greater atherosclerosis

Youths with type 1 diabetes, especially boys, already show early signs of cardiovascular disease by their teen-age years, according to researchers from the Keck School of Medicine of the University of Southern California and Childrens Hospital Los Angeles.

13 Jun 2005

Rimonabant study shows significant improvements in HbA1c and cardiometabolic risk factors in people with type 2 diabetes

The reported results of a one-year phase III study in 1045 people with type 2 diabetes treated with rimonabant, the first in a new class of therapeutic agents called selective CB1 Blockers, were that rimonabant 20 mg significantly improved HbA1c (a measure of blood sugar control), dyslipidemia (abnormal levels of fat in the blood), and systolic blood pressure with a concomitant substantial reduction in abdominal obesity in people with type 2 diabetes treated with oral anti-diabetic medications and requiring further control.

12 Jun 2005

Muraglitazar lowers blood glucose and helps dyslipidemia seen in diabetes

A novel compound provides long-term lowering of blood glucose levels and improves plasma lipids (fats) that are often a problem in people with type 2 diabetes -- all in a once-daily pill, according to a report presented today at the American Diabetes Association's 65th Annual Scientific Sessions.

12 Jun 2005

Patients on hypertension and lipid-lowering medications not sticking to prescriptions

A new study designed to look at how well patients with high blood pressure and dyslipidemia (high cholesterol levels) coped with their medication, has discovered that within six months many patients fail to take blood pressure or cholesterol medication properly.

24 May 2005